Mild cognitive impairment Alzheimer'
Conditions
Interventions
None listed
Sponsors
National Center of Neurology and Psychiatry Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ?Alzheimer disease (AD) patients (mild AD, mild cognitive impairment) Common parts 1) Age of ranging from 60 to 80 years, regardless of gender 2) Being outpatient of the dementia center of our hospital 3) Patients having the ability to provide informed consent A. Mild AD a) Diagnosed as probable AD based on NIA-AA (National Institute on Aging and Alzheimer's Association) or DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) b) MMSE 20-23 c) Clinical Dementia Scale (CDR) global score 0.5 or 1 B. Mild cognitive impairment due to AD a) Diagnosed as MCI due to AD based on NIA-AA or DSM-5 b) MMSE 24-27 c) CDR global score 0.5 and memory domain 0.5 ?Healthy controls 1) Age of ranging from 60 to 80 years, regardless of gender 2) Normal cognition (MMSE 28 or more and CDR global score 0 and normal range by years of education in delayed recall of the Wechsler Memory Scale-Revised : 9 or higher for 16 years of education, 5 or higher for 10-15 years, and 3 or higher for 0-9 years) 3) Patients having the ability to provide informed consent
Exclusion criteria
Exclusion criteria: 1) Patients diagnosed with a dementia other than AD 2) Subjects with possible Dementia with Lewy Bodies (DLB) ?MDS-UPDRS part 3 of 10 or more ?an abnormality in the neurological examination ?history of parkinsonism in first-degree relatives ?the Beck Depression Inventory ver,2 score of 12 or more ?Who has a possibility of a rapid eye movement sleep behavior disorder (RBD) evaluated by the RBD screening questionnaire ?abnormal MIBG scintigraphy or [123I]FP-CIT SPECT, either in the past or during the study period 3) having abnormalities (e.g.brain tumors, cerebrovascular malformations, cortical infarcts) in MRI 4) who has a cardiac pacemaker, metals in the body, tattoo, and claustrophobia 5) have suffered from major depression or bipolar disorder within the past year, or have a history of schizophrenia in the past 6) subjects judged by the principle investigator not to be eligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlations between quantitative assessment of cerebral amyloid and melanin in the locus ceruleus | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic accuracy of qualitative and quantitative assessment of melanin in the locus ceruleus using Standard of Truth (SOT) for quantitative assessment of amyloid | — |
Countries
Japan
Contacts
Public ContactYoko Shigemoto
National Center of Neurology and Psychiatry Hospital Department of Radiology
Outcome results
None listed